The Canadian Pulmonary Fibrosis Foundation has listed a series of clinical trials on their website that are currently enrolling patients in Canada suffering from pulmonary fibrosis, all in a bid to increase participation in trials that could lead to the next major drug discovery for the disease. The Foundation maintains a section on their website with an updated list of drug developers and testing facilities that are conducting studies on IPF and seeking to enroll patients. However, the organization also reminds patients who are interested in participating in investigational studies to consult their physician first.
The first study listed by the Canadian Pulmonary Fibrosis Foundation, Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis, is supported by Boehringer Ingelheim. Enrolling in both Hamilton, ON, and Halifax, NS, the study is a 12-month multi-center, prospective, randomized, placebo controlled, double blind clinical trial, which aims to evaluate the impact of nintedanib 150mg BID on the progression of idiopathic pulmonary fibrosis. Therefore, researchers will measure the HRCT, lung function, 6MWT, biomarkers, and PROs, and monitor the parameters 18 months after the study.
With sites in Kelowna, BC; Vancouver, BC; Hamilton, ON: Toronto, ON; Montreal, QC, and Quebec City, QC, researchers are also looking to recruit patients to evaluate the efficacy and safety of Simtuzumab (GS-6624) in the treatment of IPF in a phase 2 study supported by Gilead Sciences. The study, entitled A Phase 2 Study to See if Simtuzumab (GS-6624) is Safe and Works in Idiopathic Pulmonary Fibrosis (IPF) (RAINIER), plans to assess simtuzumab as an effective antibody that targets the LOXL2, which participates in the development of the disease. Therefore, the scientists aim to understand if by blocking its pathway the medication is consequently able to slow the progression of the disease.
Lebrikizumab will also be evaluated in patients suffering from IPF in a study sponsored by Hoffmann-La Roche entitled, A Study of Lebrikizumab in Patients With Idiopathic Pulmonary Fibrosis. Open centers for the study are enrolling in Vancouver, BC; London, ON; Hamilton, ON; Ste. Foy, QC; and Moncton, NB. The antibody lebrikizumab is dissolved in a liquid solution and injected under the skin in order to attach to interlukin-13 (IL-13) and slow the progression of the disease.
Finally, MedImmune LLC is also supporting an ongoing phase 2, randomized dose-ranging clinical trial with the main purpose of evaluating the efficacy of tralokinumab in adult patients suffering from IPF. The study, entitled A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults WithIdiopathic Pulmonary Fibrosis, is currently enrolling patients in Vancouver, BC; Edmonton, AB; Windsor, ON; Toronto, ON; Montreal, QC; and Quebec City, QC.